公开(公告)号：US20180125849A1

公开(公告)日：2018-05-10

申请号：US15867425

申请日：2018-01-10

Applicant: Novartis AG

Inventor： Graham Charles Bloomfield ,  Ian Bruce ,  Brian Cox ,  Lee Edwards ,  Judy Fox Hayler ,  Catherine Howsham

IPC: A61K31/519 ,  A61K31/5377 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  C07D487/04

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

公开(公告)号：US08901134B2

公开(公告)日：2014-12-02

申请号：US14261890

申请日：2014-04-25

Applicant: Novartis AG

Inventor： Graham Charles Bloomfield ,  Ian Bruce ,  Brian Cox ,  Lee Edwards ,  Judy Fox Hayler ,  Catherine Howsham

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  C07D487/04

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物，其中R1-R3和Y在说明书中定义，及其用于治疗其中涉及pi3激酶的病症。

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.